| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
c-FMS kinase (CSF-1R, colony-stimulating factor 1 receptor) (potent inhibitor, IC50 = 24 nM / 0.024 μM).
|
|---|---|
| ln Vitro |
In vitro, c-Fms-IN-2 is a potent inhibitor of c-FMS kinase with an IC50 of 24 nM (0.024 μM). It is a FMS kinase inhibitor. Quantitative data on cellular activity or selectivity against other kinases is not detailed in publicly available sources.
|
| ln Vivo |
No detailed in vivo activity data is publicly available for c-Fms-IN-2. As a c-FMS kinase inhibitor, it may have potential for in vivo studies in oncology and inflammatory diseases, but specific animal model data has not been reported in available literature.
|
| Enzyme Assay |
No specific cell-free kinase assay protocol is detailed for c-Fms-IN-2. For kinase inhibitors, typical cell-free assays include radiometric or fluorescence-based kinase activity assays using purified c-FMS kinase, ATP, and a peptide substrate. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
Cellular c-FMS kinase inhibition is assessed in cells expressing c-FMS (e.g., macrophage cell lines). Cells are treated with serial dilutions of c-Fms-IN-2, and c-FMS autophosphorylation or downstream signaling (e.g., ERK, Akt phosphorylation) is measured by Western blot. Cell proliferation or survival assays can also be performed.
|
| Animal Protocol |
No in vivo animal experimental protocol is publicly available for c-Fms-IN-2. For similar c-FMS inhibitors, typical in vivo studies involve oral or intraperitoneal administration in murine models of cancer or inflammatory diseases, with endpoints including tumor volume, macrophage infiltration, and inflammatory biomarker analysis.
|
| ADME/Pharmacokinetics |
Molecular weight: 339.39 g/mol; molecular formula: C19H21N3O3. CAS No.: 791587-67-2. Purity: typically ≥99%. SMILES: CC1CCN(CC1)c1ccc(CO)cc1NC(=O)c1ccc(o1)C#N. Storage: typical for small-molecule kinase inhibitors (desiccated, protected from light, -20°C).
|
| Toxicity/Toxicokinetics |
No toxicity data is publicly available. As a kinase inhibitor, standard toxicological profiling (cytotoxicity in multiple cell lines, hERG assay, Ames test) would be required for further development.
|
| References | |
| Additional Infomation |
c-Fms-IN-2 is a research-grade compound, not approved for therapeutic use. It is primarily used as a pharmacological tool for studying c-FMS kinase function, macrophage biology, and potential therapeutic applications in oncology and inflammatory diseases. No clinical trials have been reported. Its mechanism involves c-FMS kinase inhibition.
|
| Molecular Formula |
C19H21N3O3
|
|---|---|
| Molecular Weight |
339.388344526291
|
| Exact Mass |
339.158
|
| CAS # |
791587-67-2
|
| PubChem CID |
9884318
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
2.7
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
25
|
| Complexity |
509
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N#CC1=CC=C(C(NC2C(N3CCC(C)CC3)=CC=C(CO)C=2)=O)O1
|
| InChi Key |
NNPCFFIJVKYGHR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H21N3O3/c1-13-6-8-22(9-7-13)17-4-2-14(12-23)10-16(17)21-19(24)18-5-3-15(11-20)25-18/h2-5,10,13,23H,6-9,12H2,1H3,(H,21,24)
|
| Chemical Name |
5-cyano-N-[5-(hydroxymethyl)-2-(4-methylpiperidin-1-yl)phenyl]furan-2-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~294.65 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.37 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9465 mL | 14.7323 mL | 29.4646 mL | |
| 5 mM | 0.5893 mL | 2.9465 mL | 5.8929 mL | |
| 10 mM | 0.2946 mL | 1.4732 mL | 2.9465 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
